Business Wire

Destroy Duchenne selects DNA Nanobots as Partner to Develop Non-Viral Gene Delivery Solution for Duchenne Muscular Dystrophy

NORCO, Calif. & COLUMBUS, Ohio--(BUSINESS WIRE)--Destroy Duchenne, a nonprofit organization founded by DMD patient, Elijah Stacy that aims to Complete the Cure TM for Duchenne Muscular Dystrophy (DMD) ...
Yahoo Finance

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Dyno to receive a $15 million fee plus potential milestone and royalty payments under terms established in the companies' 2021 research collaboration. This marks Dyno’s second capsid licensed from its ...
Benzinga.com

Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?

Dyne Therapeutics Inc (NASDAQ:DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with ...
Phys.org

NanoCas, a smaller version of CRISPR tested with a single AAV, delivers on-target results

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform gene editing in non-liver tissues, including skeletal muscle, using a ...
Morningstar

Dyno Therapeutics Unveils Best-in-Class Dyno-bn8 AAV Vector for Muscle Gene Therapies, Achieving Therapeutic Delivery With Improved Safety Potential

Non-human primate study results demonstrate improvements in skeletal and cardiac muscle delivery efficacy, safety potential, human translatability, and manufacturability over prior AAV capsids ...